The class of Smad6 inhibitors constitutes a group of chemical compounds strategically designed to modulate the activity of Smad6, a crucial regulator within the transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP) signaling pathways. While direct inhibitors specifically targeting Smad6 are limited, a spectrum of chemicals exerts their effects indirectly by influencing key components within the TGF-β and BMP pathways. A prominent category within this class involves inhibitors of TGF-β type I receptors, such as SB-431542, RepSox, GW788388, SD-208, LY364947, A83-01, and EW-7197. These compounds selectively target receptors like ALK5, a key player in the TGF-β signaling pathway. Given Smad6's intricate involvement in the negative regulation of TGF-β signaling, the inhibition of these receptors indirectly impacts Smad6 activity. For instance, compounds like SB-431542 and RepSox specifically focus on ALK5, disrupting the TGF-β signaling cascade and potentially altering Smad6 function.
Another significant group comprises inhibitors of BMP type I receptors, including LDN-193189, Dorsomorphin, LDN-214117, and LDN-212854. These chemicals selectively target receptors like ALK2 and ALK3 within the BMP pathway. As Smad6 plays a vital role in BMP signaling, these inhibitors indirectly modulate Smad6 activity by influencing the dynamics of the BMP pathway. The intricate interplay between these inhibitors and the signaling cascades involving Smad6 reflects the complex regulatory network within cellular responses mediated by Smad6. In summary, the Smad6 inhibitors class presents a diverse array of chemicals with the potential to impact Smad6 activity indirectly through the modulation of TGF-β and BMP signaling pathways.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin is a selective inhibitor of BMP type I receptors, including ALK2, ALK3, and ALK6. As a BMP pathway inhibitor, dorsomorphin has the potential to influence Smad6 indirectly by altering BMP signaling dynamics. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
RepSox is an inhibitor of the TGF-β type I receptor, targeting ALK5 and ALK4. Its inhibition of TGF-β signaling may lead to downstream effects that impact Smad6 activity, providing a potential indirect modulation. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a selective inhibitor of the TGF-β type I receptor ALK5. By specifically blocking ALK5, it interferes with the TGF-β signaling pathway, potentially influencing Smad6 activity indirectly. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY364947 is a selective inhibitor of TGF-β type I receptor ALK5. Its interference with ALK5 signaling can impact the TGF-β pathway, potentially influencing Smad6 activity indirectly. | ||||||
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 1432597-26-6 | sc-476318 | 5 mg | $380.00 | ||
LDN-212854 is a selective inhibitor of BMP type I receptors ALK2 and ALK3. As a BMP pathway inhibitor, it may intersect with Smad6 function, providing a potential indirect modulation of Smad6 activity. | ||||||
IN-1130 | 868612-83-3 | sc-507462 | 25 mg | $435.00 | ||
IN-1130 is a selective TGF-βRI kinase inhibitor targeting ALK5. By inhibiting ALK5, it interferes with the TGF-β signaling pathway, potentially influencing Smad6 activity indirectly. |